Zavante Therapeutics is a technology company.
Zavante Therapeutics has raised $45.0M across 1 funding round.
Zavante Therapeutics has raised $45.0M in total across 1 funding round.
Zavante Therapeutics has raised $45.0M in total across 1 funding round.
Zavante Therapeutics's investors include Aisling Capital, Frazier Healthcare Partners, Novo Ventures.
# Zavante Therapeutics: Clarification on Company Classification
Zavante Therapeutics is not a technology company—it is a biopharmaceutical company. The premise of your query contains an inaccuracy that should be corrected before proceeding with analysis.
Zavante Therapeutics is a clinical-stage biopharmaceutical company focused on developing injectable antibiotics to treat serious, life-threatening infections in hospitalized patients, particularly those caused by multi-drug resistant (MDR) bacteria[1]. The company addresses a critical unmet medical need in hospital settings where conventional antibiotics have become ineffective.
The company's lead product candidate is fosfomycin (Contepo), an injectable antibiotic that had completed Phase 2/3 clinical studies as a treatment for complicated urinary tract infections[1]. This positions Zavante in the pharmaceutical development space rather than the technology sector, focusing on drug discovery and clinical validation rather than software, hardware, or digital platforms.
Zavante Therapeutics was founded in 2015[1] and operated as an independent biopharmaceutical entity before being acquired. The company was formerly known as SG Pharmaceuticals before rebranding to Zavante[1]. During its independent operations, the company raised $65.29 million in total funding[1], demonstrating investor confidence in its clinical-stage pipeline and therapeutic approach.
The company's trajectory culminated in an acquisition by Nabriva Therapeutics (NASDAQ: NBRV), an Ireland-based pharmaceutical company, in July[1]. This acquisition reflected the value of Zavante's lead drug candidate and its progress through clinical development stages.
Zavante operates within the biopharmaceutical industry, not the technology sector. The distinction is important for investment analysis, as biopharmaceutical companies face different regulatory pathways (FDA approval), longer development timelines, and different risk-return profiles compared to technology firms. Understanding this classification is essential for proper sector analysis and investment evaluation.
Zavante Therapeutics has raised $45.0M across 1 funding round. Most recently, it raised $45.0M Series A in March 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2016 | $45.0M Series A | Aisling Capital, Frazier Healthcare Partners, Novo Ventures |